The PBR1000 Summary: Sarepta Therapeutics(NASDAQ: SRPT)
Business Description: “At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
Our work is purposeful, audacious, urgent. Our commitment to do well by patients is unyielding as we build our position as the world’s leader in precision genetic medicine.”
Business Name: Sarepta Therapeutics, Inc
Sector: Healthcare; Industry: Biotechnology and Medical Research
Ticker: NASDAQ: (Common)
Fiscal Year Ending: December
Stock Price, Analysts Forecast and Recommendation for SRPT on 08/14/24:
- Stock Price: $133.08
- Analysts Forecasted 12 Month Average Stock Price: $195.83
- Analysts Forecasted 12 Month Change: +47.15%
- Analysts Recommendation: Buy, 4.75/5.00, based on 20 forecasts, 16 as a Strong Buy
- Current Forecast: Link
Some of the 31 Current The PBR1000 Rankings for SRPT on 08/14/24:
- 990 By Annual Revenues(12/31/23): $1.243 billion; Profits/(Loss): ($0.536) billion
- Earnings Per Share: ($5.80); Annual Dividend Per Share: $ 0.00; Annual Dividend Yield: 0.00%
- 842 By Assets(12/31/23): $3.265 billion; Equity: $0.859 billion
- 482 By Market Capitalization(07/31/24): $13.45 billion
- 959 By Employees(12/31/23): 1,314
The SRPT Investors Page: SRPT
The SRPT SEC Filings Page(EDGAR): SRPT
On July 31, 2024, SRPT was on The PBR25 Top Buy Stocks. To find out who else is click here!
PBRMarketTools.com provides The PBR1000, a compilation of 1,000 of the largest publicly held companies with primary operations in the US. These companies generate $20 trillion in annual revenues, more than all other US companies combined. The PBR1000 Monthly Snapshots provides these 1,000 companies in Excel format, includes 19 worksheets with 31 rankings, over 200 data/information points, hotlinks to key data, and important news items per company.
Disclaimers: The PBR1000 is compiled from a variety of publicly available resources. As such, PBRMarketTools.com is not responsible for the data itself. Any liability for the representations or decisions based on the data is solely the responsibility of the authorized user, not PBRMarketTools.com, its employees or affiliates. PBRMarketTools.com is an independent business intelligence service providing news, data, and analysis. PBRMarketTools.com research should not be regarded as investing recommendations or advice. PBRMarketTools.com is not a financial advisory or stock brokerage firm and has no affiliation with such organizations.
Empowering Astute Business Leaders and Shrewd Investors
Through The PBR1000 US Public Companies Analytics!
This The PBR1000 Summary is provided by:
Copyright © 2024 by Pax Business Resources, LLC, All Rights Reserved.
XH14-LP
